-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ — SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and…
